Impact of celecoxib restrictions in medicare beneficiaries with arthritis

American Journal of Managed Care

Volumn 17, Issue 7, 2011, Pages 503-512

  Louder, Anthony M ^a   Joshi, Ashish V ^b   Ball, Amy T ^a   Cappelleri, Joseph C ^b   Deminski, Michael C ^b   Sanchez, Robert J ^b  

^a WFP6W ^*  (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; OSTEOARTHRITIS; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; UNITED STATES;

EID: 79960821941     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-1915.
2. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, P I: osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38(11):1535-1540.
3. Bérard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol. 2000;27(7):1648-1655. (Pubitemid 30462806)
4. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):31S-38S. (Pubitemid 28378015)
5. Lanas A, Serrano P, Bajador, Esteva F, Benito R, Sáinz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997;112(3):683-689. (Pubitemid 27113792)
6. Laine L, Connors LG, Reicin A. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124(2):288-292. (Pubitemid 36169245)
7. Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging. 2007;24(2):121-131. (Pubitemid 46327571)
8. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109(5):359-363.
9. Smalley WE, Ray WA, Daughtery JR, Griffin MR. Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141(6):539-545.
10. Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2-specific inhibitors. Am J Med. 2001;110(suppl 3A):6S-12S. (Pubitemid 32155397)
11. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-2194. (Pubitemid 39507631)
12. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med. 1995;332(24):1612-1617.
13. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered copayment drug coverage and use of nonsteroidal antiinflammatory drugs. Arch Intern Med. 2004;164(15):1679-1684. (Pubitemid 39037948)
14. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98(7);1300-1305. (Pubitemid 351948005)
15. Lanas A, Garcia-Rodriguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633-1641.
16. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case mix instrument. Med Care. 2003;41(6):761-774.
17. Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41(6):753-760.
18. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12(2):110-119.
19. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol. 2000;1(2):185-202. (Pubitemid 32798848)
20. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther. 2004;26(9):1518-1532. (Pubitemid 39572162)
21. Carroll NV, Smith JC, Berringer RA, Oestreich GL. Evaluation of an automated system for prior authorization: a COX-2 inhibitor example. Am J Manag Care. 2006;12(9):501-508. (Pubitemid 44412032)
22. Johnell K, Fastbom J. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study. Clin Drug Investig. 2008;28(11):687-695.